Public investors are rewarding profitability, sector alignment, and valuation discipline, not just top-line growth. The IPO window remains narrow, demanding stronger fundamentals and clearer exit strategies. After years of volatility,...

Valuations are resetting across US venture markets as down rounds normalize, exits remain constrained, and capital concentrates in a few dominant sectors. For investors, this is both a moment of...

Biopharma venture capital (VC) dealmaking slowed sharply in 2Q25, with investment consolidating into select, larger transactions targeting lower-risk opportunities. Investors are prioritizing clinically validated assets, AI-enabled R&D models, and M&A-driven...

AI and ML VC (venture capital) investment reached record highs in 1Q25, driven by the scale of infrastructure and the breadth of applications. Yet capital remains unevenly distributed, forcing investors...

Venture and private equity (PE) activity in medtech is rebounding after a multi-year lull, led by platform-driven innovation and disciplined capital deployment. Yet regulatory ambiguity and muted exit markets demand...

Midyear 2025 reveals a bifurcated venture market defined by concentrated capital, stalled liquidity, and selective exits. AI-backed leaders advance, while most startups face funding constraints and delayed outcomes. Despite a...

Enterprise SaaS M&A in 1Q25 showed a market realigning around pricing discipline, strategic intent, and long-term value. Despite lower headline deal values, activity remained steady and focused, reflecting a shift...

US venture capital (VC) activity in 1Q25 remained highly concentrated, with AI deals dominating both capital and headlines. Yet beneath the surface, liquidity stayed tight, valuations fragmented, and returns increasingly...

In 2024, climate tech startups found themselves under pressure, grappling with shrinking capital flows and intensifying investor scrutiny. Amid macroeconomic headwinds, AI-driven capital redirection, and mounting policy uncertainty, venture investors...

Biopharma modalities' venture capital (VC) investments are becoming more selective, favoring proven assets over high-risk innovation. While cardiometabolic drugs and AI-driven drug discovery continue to attract capital, investors are shifting...